Attention deficit hyperactivity disorder and mental retardation;Trastorno por déficit de atención e hiperactividad y retraso mental

Revista de Neurologia

Volumn 42, Issue SUPPL. 2, 2006, Pages

  Fernandez Jaen A ^a  

^a HOSPITAL LA ZARZUELA   (Spain)

Author keywords

ADHD; Attention deficit; Hyperactivity; Mental retardation; Methylphenidate; Risperidone

Indexed keywords

CLONIDINE; FENFLURAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT; RISPERIDONE;

ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; MENTAL DEFICIENCY; MENTAL FUNCTION; NEUROLOGIC DISEASE; PSYCHOMETRY; UNSPECIFIED SIDE EFFECT;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; HUMANS; MENTAL RETARDATION;

EID: 33947167052     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Pearson DA, Aman MG. Ratings of hyperactivity and developmental indices: should clinicians correct for developmental level? J Autism Dev Disord 1994; 24: 395-411.
2. Bourneville E. Le traitement medico-pedagogigue des différentes formes de l'idiotie. Paris: Alcan; 1897.
3. Still GF. The coulstonian lecture on some abnormal physical conditions in children. Lancet 1902; 1: 1008-12.
4. Linna SL, Moilanen I, Ebeling H, Piha J, Kumpulainen K, Tamminen T, et al. Psychiatric symptoms in children with intellectual disability. Eur J Child Adolesc Psychiatry 1999; 8: 77-82.
5. Strome P, Diseth TH. Prevalence of psychiatric diagnoses in children with mental retardation: data from a population-based study. Dev Med Child Neurol 2000; 42: 266-70.
6. Dekker MC, Koot HM. DSM-IV disorders in children with borderline to moderate intellectual disability, I: prevalence and impact. J Am Acad Child Adolesc Psychiatry 2003; 42: 915-22.
7. Emerson E. Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. J Intel Disab Res 2003; 47: 51-8.
8. Buelow JM, Austin JK, Perkins SM, Shen J, Dunn DW, Pastenau PS. Behaviour and mental health problems in children with epilepsy and low IQ. Dev Med Child Neurol 2003; 45: 683-92.
9. Barnard L, Pearson J, Rippon L, O'Brien G. Behavioural phenotypes of genetic syndromes: summaries, including notes on management and therapy. In O'Brien G, ed. Behavioural phenotypes in clinical practice. London: Mac Keith Press; 2002. p. 169-227.
10. Bregman JD, Leckman JF, Ort SI. Fragile X syndrome: genetic predisposition to psychopathology. J Autism Dev Dis 1988; 18: 343-54.
11. Tassone F, Hagerman RJ, Taylor AK, Mills JB, Harris SW, Gane LW, et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000; 91: 144-52.
12. Munir F, Cornish KM, Wilding J. A neuropsychological profile of attention deficits in young males with fragile X syndrome. Neuropsychol 2000; 38: 1261-70.
13. Cornish K, Munir F, Wilding J. Perfil neuropsicológico y conductual de los déficit de atención en el síndrome X frágil. Rev Neurol 2001; 33 (Supl): S24-9.
14. Brown JH, Johnson MH, Paterson SJ, Gilmore R, Longhi E, Karmiloff-Smith A. Spatial representation and attention in toddlers with Williams syndrome and Down syndrome. Neuropsychol 2003; 41: 1037-46.
15. Andreou G, Galanopoulou C, Gourgoulianis K, Karapetsas A, Polyvdas P. Cognitive status in Down syndrome individuals with sleep disordered breathing deficits (SDB). Brain Cogn 2002; 50: 145-9.
16. Miller ML, Fee VE, Netterville AK. Psychometric properties of ADHD rating scales among children with mental retardation I: reliability. Res Dev Disabil 2004; 25: 459-76.
17. Santosh PJ, Baird G. Psychopharmacotherapy in children and adults with intellectual disability. Lancet 1999; 354: 233-42.
18. Handen BL, Breaux AM, Gosling A, Ploof DL, Feldman H. Efficacy of methylphenidate among mentally retarded children with attention deficit hyperactivity disorder. Pediatrics 1990; 86: 922-30.
19. Pearson DA, Santos CW, Roache JD, Casas CD, Loveland KA, Lachar D, et al. Treatment effects of methylpehidate on behavioral adjustment in children with mental retardation. J Am Acad Child Adolesc Psychiatry 2003; 42: 209-16.
20. Handen BL, Feldman H, Lurier A, Murray PJH. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry 1999; 38: 805-12.
21. Handen BL, Janosky J, McAuliffe S, Breaux AM, Feldman H. Prediction of response to methylphenidate among children with ADHD and mental retardation. J Am Acad Child Adolesc Psychiatry 1994; 33: 1185-93.
22. Handen BL, Feldman H, Gosling A, Breaux AM, McAuliffe S. Adverse effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry 1991; 30: 241-5.
23. Aman MG, Smedt G, Derivan A, Lyons B, Findling RL. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337-46.
24. Agarwal V, Sitholey P, Kumar S, Prasad M. Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation. Ment Retard 2001; 39: 259-67.
25. Aman MG, Kern RA, McGhee DE, Arnold LE. Fenfluramine and methylphenidate in children with mental retardation and ADHD: clinical and side effects. J Am Acad Child Adolesc Psychiatry 1993; 32: 851-9.
26. Aman MG, Kern RA, McGhee DE, Arnold LE. Fenfluramine and methylphenidate in children with mental retardation and ADHD: laboratory effects. J Am Acad Child Adolesc Psychiatry 1993; 23: 491-506.
27. Blum NJ, Mauk JE, McComas JJ, Mace FC. Separate and combined effects of methylphenidate and a behavioral intervention on disruptive behavior in children with mental retardation. J Appl Behav Anal 1996; 29: 305-19.